IaS01: EAN/PNS: Treatable inheritable neuropathies: things become real

Saturday, 1 Jul, 08:30 – 10:00 CEST

The aim of the session is to train clinicians in suspecting, diagnosing and treating hereditary neuropathies that commonly are misdiagnosed as more frequent conditions (either inherited or acquired) and are treatable. These include different metabolic disorders and proteinopathies, diagnoses which should not be missed.

TC05: EAN/PNS: Small fiber neuropathy – update on diagnosis and treatment (L1)

Saturday, 1 Jul, 15:30 – 18:45 CEST

Small fiber neuropathy is frequently suspected in patients with acral pain of unknown etiology. It can also accompany a number of systemic diseases. This course will give a comprehensive description of diagnostics, etiology, and treatment of small fiber neuropathy.

TC09: Diagnosis and treatment of GBS, CIDP and autoimmune nodopathies (L3)

Sunday, 2 Jul, 15:30 – 18:45 CEST

The new EAN/PNS GBS and CIDP diagnosis and treatment guidelines constructed by an international task force of disease experts according to modern GRADE methodology will be presented. The GBS guideline is the first ever and the CIDP guideline is a long awaited revised version of the 2010 guideline. The state-of-the-art management recommendations for GBS and CIDP will be discussed.

The autoimmune nodopathies, a novel group of neuropathies resembling CIDP but distinct from it, are caused by nodal/paranodal cell adhesion molecule antibodies mainly of the IgG4 subclass. The special features associated with these will be discussed as will be the treatment recommendations. Biomarkers helpful for the diagnosis and follow-up of these autoimmune neuropathies are being developed.

Together with an increasing number of validated outcome measures, they are helpful instruments to monitor the disease course and treatment response and to reshape treatment of CIDP and autoimmune nodopathies.

ST36: Scientific Theater Session: Advances in Guillain-Barré syndrome (GBS)

Monday, 3 Jul, 15:30 – 16:00 CEST

Guillain-Barré syndrome (GBS) is a heterogeneous disorder that requires early diagnosis and treatment. The new EAN/PNS GBS Guideline aids in the diagnostic process and treatment of GBS. An important other advance are results of the International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study. IGOS contains data and biological samples of 2000 patients included from over 140 centers across five continents. It enables to identify predictors of disease onset, subtype, course and outcome. Results and new possibilities using data of this large GBS study will be discussed.

PNS/ASNA Joint Plenary Session

Saturday, 12 August 2023, 13.30 – 14.45 ICT

PLENARY SESSION 4

Chairs: Dr. Umapathi Thirugnanam (Singapore), Dr. Le Minh (Vietname)

• Long Live the Art of Clinical Neuropathy
  Dr. Hadi Manji (UK)
• COVID-19 and the PNS
  Dr. James Sejvar (US)
• Title TBD
  Speaker TBD

PNS/NEUROdiab Joint Session

Saturday, 30 September 2023, 15.45 – 16.55 EEST

Insights Into the Nerve Damage in Diabetic Neuropathy
Chairs: Dr. Brian Callaghan (USA), Dr. Dinesh Selvarajah (UK)

• The Role of Schwann Cell-Axon Interactions in Metabolic Disease
  Dr. Stephanie Eid (US)
• The Role of Mitochondria and Bioenergetic Failure in Painful Neuropathy
  Dr. Daniela Menichella (US)
• The Role of Nerve Vessels
  Dr. Zoltan Kender (Germany)

Updates on CMT, GBS, and Diabetic Neuropathy

Wednesday, 1 November 2023, 13:30 – 15:00 p.m. CST (US/Canada)

Speakers: Ruple S. Laughlin, MD; Vera Fridman, MD; Mazen M. Dimachkie, MD

Review advances in the development of treatments for Charcot Marie Tooth disease (CMT); discuss the activities and results of research collaborations through the International Guillain Barre Outcome Study (IGOS); and review the clinical picture, diagnosis and treatment of diabetic radiculoplexus neuropathy.

 This activity has been planned an implemented in accordance with the accreditation requirements and policies of the ACCME through joint provider ship of AANEM and the Peripheral Nerve Society. The AANEM is accredited by the ACCME to provide continuing medical education for physicians.

Basic-Translational-Clinical Roundtables

Sunday, 12 November, 10.30 – 12.00 EST (US/Canada)

Chair: Ahmet Hoke, MD, PhD
Speakers: Michael Coleman, PhD; Shilpa Sambashivan, PhD

Distal axon degeneration is a principal cellular event resulting in symptoms in peripheral neuropathies. In this rountable, advances in our understanding of the molecular mechanisms of programmed axon degeneration and its relevance to slow distal axon degeneration seen in peripheral neuropathies will be discussed and therapeutic targets and biomarkers will be highlighted.